Barclays Has Lowered Expectations for Sotera Health (NASDAQ:SHC) Stock Price

Sotera Health (NASDAQ:SHC) had its price target cut by research analysts at Barclays from $22.00 to $20.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Barclays‘s price objective would suggest a potential upside of 20.59% from the company’s previous close.

Other equities research analysts have also recently issued reports about the stock. Weiss Ratings cut shares of Sotera Health from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, October 23rd. Wall Street Zen raised Sotera Health from a “buy” rating to a “strong-buy” rating in a report on Sunday, October 25th. JPMorgan Chase & Co. lowered Sotera Health from a “neutral” rating to an “underweight” rating and set a $17.00 price objective for the company. in a research note on Wednesday, October 14th. Piper Sandler restated an “overweight” rating and issued a $25.00 target price on shares of Sotera Health in a report on Tuesday, September 8th. Finally, Citigroup boosted their target price on Sotera Health from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $21.12.

Sotera Health Price Performance

Shares of SHC stock traded up $0.56 during midday trading on Wednesday, reaching $16.59. 2,190,642 shares of the company were exchanged, compared to its average volume of 2,701,423. The company’s 50 day moving average price is $18.42 and its two-hundred day moving average price is $17.02. The company has a market cap of $4.73 billion, a P/E ratio of 29.06 and a beta of 1.94. Sotera Health has a 12 month low of $13.09 and a 12 month high of $19.85. The company has a debt-to-equity ratio of 3.33, a quick ratio of 2.55 and a current ratio of 2.80.

Sotera Health (NASDAQ:SHC) last announced its earnings results on Tuesday, November 3rd. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.27 by $0.02. The firm had revenue of $324.89 million for the quarter, compared to analysts’ expectations of $319.86 million. Sotera Health had a return on equity of 40.12% and a net margin of 13.44%. The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.26 earnings per share. On average, sell-side analysts expect that Sotera Health will post 0.87 earnings per share for the current year.

Insider Activity at Sotera Health

In other Sotera Health news, Chairman Michael Petras, Jr. sold 850,000 shares of Sotera Health stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $18.50, for a total transaction of $15,725,000.00. Following the transaction, the chairman directly owned 3,969,393 shares in the company, valued at approximately $73,433,770.50. The trade was a 17.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Michael Rutz sold 150,000 shares of the business’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $18.84, for a total transaction of $2,826,000.00. Following the sale, the insider directly owned 334,279 shares in the company, valued at approximately $6,297,816.36. This trade represents a 30.97% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 1,294,515 shares of company stock valued at $23,999,528. 15.36% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Darsana Capital Partners LP raised its holdings in Sotera Health by 3.8% during the second quarter. Darsana Capital Partners LP now owns 27,000,000 shares of the company’s stock valued at $479,250,000 after buying an additional 1,000,000 shares in the last quarter. BlackRock Inc. bought a new stake in shares of Sotera Health during the 2nd quarter worth $428,635,000. Sculptor Capital LP acquired a new position in Sotera Health in the 2nd quarter valued at $426,000,000. Janus Henderson Group PLC raised its holdings in Sotera Health by 35.3% in the 1st quarter. Janus Henderson Group PLC now owns 9,162,191 shares of the company’s stock worth $131,413,000 after acquiring an additional 2,390,132 shares during the period. Finally, Jupiter Topco LLC bought a new position in Sotera Health in the 2nd quarter worth $149,137,000. Hedge funds and other institutional investors own 91.03% of the company’s stock.

Key Stories Impacting Sotera Health

Here are the key news stories impacting Sotera Health this week:

• Positive Sentiment: Q3 revenue rose 4.4% year over year to $324.9 million, topping analyst expectations of about $319.9 million. Adjusted EPS was $0.29 versus the $0.27 consensus and increased 12% year over year; adjusted EBITDA rose 3.9%. Sotera Health Q3 results
• Neutral Sentiment: Management reaffirmed its 2026 outlook: constant-currency revenue growth of 5.25%–6.75% and adjusted EBITDA growth of 5.75%–7.25%. It also provided fourth-quarter revenue guidance, though the supplied report did not include the forecast figure. Fourth-quarter revenue guidance
• Negative Sentiment: The company cited softness in the European medical-device market, a demand headwind investors will monitor despite the reaffirmed full-year targets. 2026 outlook and European market conditions

About Sotera Health

Sotera Health Company (NASDAQ: SHC) is a healthcare services company focused on sterilization, laboratory testing and infection prevention. Its services support manufacturers and providers across the medical device, pharmaceutical, tissue, food safety and other healthcare-related industries.

The company operates through three primary businesses. Sterigenics provides outsourced sterilization services, including ethylene oxide, gamma irradiation and electron-beam processing. Nelson Labs offers laboratory testing, analytical services and consulting for medical devices, pharmaceuticals and other healthcare products.